Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05982561 · ClinicalTrials.gov registry record
Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
A clinical trial of Bladder Cancer, sponsored by Early is Good.
- Recruiting
- Registry status
- 500
- Enrollment target
- 3
- Study locations
NCT05982561 is a study of Bladder Cancer that is actively recruiting participants, run by Early is Good. The registered enrollment target is 500 participants, below the 12,751-participant average among 175 other Bladder Cancer trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05982561, a study of Bladder Cancer, is actively recruiting participants, sponsored by Early is Good.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 3
- Study locations
Study Summary
BCDx is a urine-based multi-omic assay for early cancer recurrence detection in patients with a history of bladder cancer. This prospective, blinded study evaluates its efficacy in detecting recurrent NMIBC, offering a noninvasive monitoring solution.
Conditions Studied
Study Locations (3)
Arkansas
- Arkansas Urology Research Center - Little Rock
Indiana
- Indiana University School of Medicine - Indianapolis
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-07-26 |
| Est. Completion | 2025-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05982561
The ClinicalTrials.gov registry entry for NCT05982561 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,751-participant average among 175 other Bladder Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Early is Good, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT05982561 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arkansas, Indiana, Missouri.
Frequently Asked Questions
What is clinical trial NCT05982561 about?
NCT05982561 is a clinical study titled "Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer". BCDx is a urine-based multi-omic assay for early cancer recurrence detection in patients with a history of bladder cancer. This prospective, blinded study evaluates its efficacy in detecting recurrent NMIBC, offering a noninvasive monitoring solution.
What is the current status of trial NCT05982561?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2023-07-26. Estimated completion is 2025-12-31.
What conditions does trial NCT05982561 study?
This clinical trial studies the following conditions: Bladder Cancer.
Who is sponsoring clinical trial NCT05982561?
This trial is sponsored by Early is Good, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05982561 being conducted?
This trial has 3 study locations across Arkansas, Indiana, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.